Resistance to anti-HER2 therapy in HER2+ breast cancer is mediated by genomic alterations that switch pathway dependence from PI3K/AKT to RAS/MAPK Meeting Abstract
| Authors: | Smith, A. E.; Chandarlapaty, S. |
| Abstract Title: | Resistance to anti-HER2 therapy in HER2+ breast cancer is mediated by genomic alterations that switch pathway dependence from PI3K/AKT to RAS/MAPK |
| Meeting Title: | 111th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 80 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2020 Apr 27-28/Jun 22-24 |
| Meeting Location: | Philadelphia, PA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-08-01 |
| Language: | English |
| ACCESSION: | WOS:000590059304151 |
| DOI: | 10.1158/1538-7445.Am2020-1910 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1910 -- Due to COVID-19 pandemic, the conference was held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
279Chandarlapaty -
6Smith
Related MSK Work